title: Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients.
abstract: OBJECTIVE
  To compare the accuracy of the nine selected algorithms for predicting warfarin dose with 586 Han Chinese patients.
  
  
  METHODS
  Genotyping of VKORC1 1639G>A, CYP2C9*2 and CYP2C9*3 variants was performed. Both the mean absolute error and ideal estimation value were used for comparison.
  
  
  RESULTS
  The top three performers were from East Asians. The algorithms from Caucasians generally performed better in the medium-dose subgroup (>3 and <7 mg/day), while the algorithms from East Asians generally performed better in the low-dose subgroup (≤ 3 mg/day). None of the algorithms performed well in the high-dose subgroup (≥ 7 mg/day).
  
  
  CONCLUSIONS
  Algorithms built for specific ethnic groups and preassigned-dose groups are suggested for better prediction.
authors.affiliation: Cardiac Surgery, Wuhan Asia Heart Hospital, 753 Jinghan Ave, Jianghan District, Wuhan, Hubei, 430022, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Peng
authors.affiliation: Hubei Vidagen Gene Technology Co., Ltd, Building C6-208, 666 Gaoxin Ave, Donghu High-Tech Developmental District, Wuhan, Hubei, 430075, China.
authors.forename: Shujun
authors.initials: S
authors.lastname: Huang
authors.affiliation: Department of Cardiology, Wuhan Asia Heart Hospital, 753 Jinghan Ave, Jianghan District, Wuhan, Hubei, 430022, China.
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Chen
authors.affiliation: Hubei Vidagen Gene Technology Co., Ltd, Building C6-208, 666 Gaoxin Ave, Donghu High-Tech Developmental District, Wuhan, Hubei, 430075, China.
authors.forename: Yayan
authors.initials: Y
authors.lastname: Yuan
authors.affiliation: Hubei Vidagen Gene Technology Co., Ltd, Building C6-208, 666 Gaoxin Ave, Donghu High-Tech Developmental District, Wuhan, Hubei, 430075, China.
authors.forename: Yajun
authors.initials: Y
authors.lastname: Yu
authors.affiliation: Cardiac Surgery, Wuhan Asia Heart Hospital, 753 Jinghan Ave, Jianghan District, Wuhan, Hubei, 430022, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Tao
authors.affiliation: Clinical Test Center, Wuhan Asia Heart Hospital, 753 Jinghan Ave, Jianghan District, Wuhan, Hubei, 430022, China.
authors.forename: Zhenlu
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Hubei Vidagen Gene Technology Co., Ltd, Building C6-208, 666 Gaoxin Ave, Donghu High-Tech Developmental District, Wuhan, Hubei, 430075, China.
authors.forename: Mousheng
authors.initials: M
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000925:Anticoagulants / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D044466:Asian People; D065729:Cytochrome P-450 CYP2C9 / Q000235:genetics; D005006:Ethnicity; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics / Q000706:statistics & numerical data*; D057285:Precision Medicine; D015203:Reproducibility of Results; D064417:Vitamin K Epoxide Reductases / Q000235:genetics; D014859:Warfarin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D044465:White People; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases
keywords: Chinese; algorithm; clinical accuracy; dose; pharmacogenetics; warfarin